Up-date on the NeoVitaA Trial: Obstacles, challenges, perspectives, and local experiences

Summary The aim of the NeoVitaA Trial is to assess the role of postnatal additional high-dose oral vitamin A supplementation for 28 days in reducing Bronchopulmonary dysplasia (BPD) or death in extremely low birth weight (ELBW) infants at 36 weeks postmenstrual age (PMA). All infants (both intervent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Wiener medizinische Wochenschrift 2017-09, Vol.167 (11-12), p.264-270
Hauptverfasser:	Meyer, Sascha, Gortner, Ludwig
Format:	Artikel
Sprache:	eng
Schlagworte:	Brief Report Bronchopulmonary Dysplasia - mortality Bronchopulmonary Dysplasia - prevention & control Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Enteral Nutrition Family Medicine General Practice Geriatrics/Gerontology Germany Gestational Age Humans Infant, Extremely Low Birth Weight Infant, Newborn Infectious Diseases Intensive Care Units, Neonatal Internal Medicine Medicine Medicine & Public Health Pharmacology/Toxicology Vitamin A - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary The aim of the NeoVitaA Trial is to assess the role of postnatal additional high-dose oral vitamin A supplementation for 28 days in reducing Bronchopulmonary dysplasia (BPD) or death in extremely low birth weight (ELBW) infants at 36 weeks postmenstrual age (PMA). All infants (both intervention and control group) will be provided with basic vitamin A (1000 IU/kg/day) in addition to trial intervention. In this short communication, we will give an up-date on obstacles, challenges as well as perspectives and potential solutions when putting into place a multicenter, double-blind, randomized trial in this cohort of extremely susceptible infants.
ISSN:	0043-5341 1563-258X
DOI:	10.1007/s10354-016-0500-z